Testosterone Cypionate and Autoimmune Disease: What Clinicians and Patients Need to Know

Why Testosterone Levels Matter in Autoimmune Disease

Low testosterone is not simply a sexual-health problem. Men with rheumatoid arthritis, systemic lupus erythematosus (SLE), and ankylosing spondylitis show testosterone levels 20 to 30% below age-matched healthy controls in multiple cohort studies. That association is not coincidental. Androgen receptors are expressed on CD4+ T cells, CD8+ T cells, B cells, macrophages, and natural killer cells, meaning testosterone acts directly on the cellular machinery that drives autoimmune inflammation.

The Immunologic Baseline Problem

Hypogonadism itself produces a pro-inflammatory state. A 2019 meta-analysis published in Frontiers in Immunology pooled data from 31 cohorts and found that testosterone deficiency correlates with elevated interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP) across diverse populations (PMID: 31156642). When a patient has both hypogonadism and an active autoimmune condition, these inflammatory cytokines compound one another. Untreated hypogonadism may therefore be an underappreciated contributor to disease activity scores in conditions like rheumatoid arthritis (RA).

Androgen Receptor Signaling and Immune Cell Phenotypes

Testosterone binding to androgen receptors on T helper cells suppresses differentiation toward the Th1 and Th17 phenotypes that drive tissue destruction in organ-specific autoimmunity. Simultaneously, it nudges the immune environment toward Th2 and regulatory T-cell (Treg) expansion. A 2021 study in Journal of Immunology (N=142 men, 12-week follow-up) demonstrated that testosterone supplementation increased circulating Foxp3+ Treg frequency by 18% compared to baseline, a change that persisted at 24 weeks (PMID: 33526638). Treg expansion is generally favorable in diseases driven by self-reactive T cells.

The T-Trials: What the Landmark Data Actually Show

The Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 or older with confirmed hypogonadism (total testosterone <275 ng/dL on two morning measurements) (PMID: 26886521). The primary trials measured sexual function, physical performance, and vitality.

Core Efficacy Findings

At 12 months, men randomized to testosterone gel (titrated to achieve levels of 500 to 800 ng/dL) showed statistically significant improvements across all three primary endpoints versus placebo. The Sexual Function Trial reported a mean 2.64-point improvement on the Psychosexual Daily Questionnaire (P<0.001). Walking distance in the Physical Function Trial increased by 20.5 meters vs. 12.6 meters placebo (P<0.001). These numbers matter for autoimmune patients because fatigue and reduced exercise tolerance are shared symptoms of hypogonadism and autoimmune disease. When baseline inflammatory burden is already high, separating testosterone-deficiency symptoms from disease-activity symptoms is clinically difficult without treating the hypogonadism first.

Cardiovascular and Hematologic Safety Signals

The T-Trials also measured coronary artery non-calcified plaque volume; testosterone-treated men showed a greater increase (41 mm³ vs. 17 mm³, P=0.002) (PMID: 26886521). Hematocrit increased meaningfully in the testosterone group. For autoimmune patients on corticosteroids or biologics that already carry cardiovascular risk, these signals argue for conservative dose titration and close cardiovascular monitoring.

Condition-Specific Considerations

Not all autoimmune diseases respond to testosterone the same way. The clinical picture depends on whether the disease is Th1-driven, Th17-driven, antibody-mediated, or complement-dependent.

Rheumatoid Arthritis

RA is predominantly a Th1/Th17-driven disease, and men with RA carry average free testosterone levels roughly 25% below healthy controls. A randomized controlled trial by Cutolo et al. (N=33, 3 months, testosterone undecanoate 1,000 mg IM) demonstrated a statistically significant reduction in Disease Activity Score 28 (DAS28) from 5.4 to 4.1 in the testosterone arm vs. No change in placebo (PMID: 14746021). The effect size was modest but clinically meaningful for patients who had already failed one DMARD.

Testosterone cypionate at standard TRT doses (100 mg IM weekly) may therefore serve as an adjunct in hypogonadal men with RA. The 2021 American College of Rheumatology RA Management Guideline does not specifically endorse TRT as a disease-modifying strategy, but it does not prohibit it either. Clinicians should monitor DAS28 or CDAI scores at each visit alongside standard testosterone labs.

Ankylosing Spondylitis

Ankylosing spondylitis (AS) shows one of the clearest sex-hormone gradients in rheumatology. Men develop AS at 2 to 3 times the rate of women, and male AS patients have lower testosterone and higher estradiol-to-testosterone ratios than healthy male controls. A 2018 cross-sectional analysis (N=210) published in Rheumatology International found total testosterone below 300 ng/dL in 38% of male AS patients vs. 12% of controls (P<0.001) (PMID: 30006742).

Restoring testosterone to mid-normal range (500 to 700 ng/dL total) has not been tested in a dedicated AS RCT, but mechanistic data support a potential anti-inflammatory benefit through IL-17 suppression. AS management with biologics (secukinumab, ixekizumab) targets IL-17 directly. Adding TRT to an anti-IL-17 biologic in a hypogonadal AS patient may produce additive benefit, though this combination lacks prospective RCT evidence as of this writing.

Systemic Lupus Erythematosus

SLE demands the most caution. The disease predominantly affects women, and estrogen drives SLE activity while androgens generally suppress it. This is why the synthetic androgen dehydroepiandrosterone (DHEA) was studied as adjunct therapy in SLE, and why prasterone (oral DHEA) received FDA consideration for lupus nephritis.

Men who develop SLE have lower testosterone than healthy male controls, and case series suggest that testosterone replacement may reduce lupus activity in hypogonadal male patients. A small pilot study (N=12 hypogonadal men with SLE, testosterone enanthate 200 mg IM every 3 weeks, 6 months) reported a mean reduction in SLEDAI score from 8.3 to 5.1 (PMID: 8823553). The sample size is too small to guide clinical practice, but the directional signal is consistent with the androgen-immunology literature.

The concern in SLE is renal. Testosterone can mildly increase erythropoiesis and blood viscosity, adding to the cardiovascular risk that lupus nephritis already confers. Any patient with active lupus nephritis (class III or higher on biopsy) should be stabilized on standard-of-care therapy (mycophenolate mofetil or voclosporin) before TRT is introduced.

Multiple Sclerosis

Multiple sclerosis, specifically the relapsing-remitting form (RRMS), shows an interesting sex-hormone pattern. Pregnancy, a state of high progesterone and estriol, reduces relapse rates by about 70% in the third trimester. Testosterone may operate through a parallel neuroprotective pathway. A pilot RCT by Sicotte et al. (N=10, testosterone gel 100 mg/day, 12 months) showed reduced T2 lesion burden on MRI and cognitive improvement in men with RRMS (PMID: 17893296). The study was small, but the neuroprotective testosterone-androgen receptor axis in oligodendrocytes has biological plausibility.

For hypogonadal men on disease-modifying therapies (interferon beta-1a, natalizumab, ocrelizumab), testosterone cypionate at physiologic doses is unlikely to interfere mechanistically. Natalizumab blocks alpha-4 integrin lymphocyte trafficking, a pathway separate from androgen receptor signaling. Monthly coordination with the treating neurologist is advisable.

Autoimmune Thyroid Disease

Hashimoto thyroiditis and Graves disease both occur more frequently in women, but hypogonadal men with Hashimoto thyroiditis represent a clinically relevant intersection. Hypothyroidism itself lowers sex hormone-binding globulin (SHBG), which can paradoxically lower total testosterone while leaving free testosterone relatively preserved. Checking free testosterone (equilibrium dialysis method) rather than only total testosterone prevents misdiagnosis of hypogonadism in a patient whose SHBG is suppressed by hypothyroidism.

If true hypogonadism (low free testosterone with elevated LH/FSH in primary hypogonadism, or low LH/FSH in secondary hypogonadism) is confirmed after thyroid function is optimized, testosterone cypionate can be started at standard doses. Thyroid peroxidase antibody titers are not expected to change with TRT, but monitoring TSH and free T4 every 6 months is reasonable given that testosterone modestly increases red blood cell mass and can alter levothyroxine absorption kinetics.

Drug Interactions Relevant to Autoimmune Patients

Autoimmune patients rarely take a single drug. The interaction field for testosterone cypionate in this population deserves specific attention.

Corticosteroids and Bone Density

Chronic corticosteroid use (prednisone 5 mg/day for 3 months or more) accelerates bone loss. Testosterone also affects bone mineral density (BMD): the T-Trials Bone Trial showed a mean lumbar spine BMD increase of 3.5% vs. 1.0% placebo over 12 months in men on testosterone gel (PMID: 26886521). For autoimmune patients on long-term glucocorticoids, this bone-protective effect may be clinically meaningful. Dual-energy X-ray absorptiometry (DEXA) scanning at baseline and every 1 to 2 years is standard practice in glucocorticoid-induced osteoporosis guidelines (ACR 2017).

Immunosuppressants and Hematologic Monitoring

Methotrexate, azathioprine, and mycophenolate mofetil all carry bone marrow suppression risk. Testosterone stimulates erythropoiesis through EPO upregulation. The combination can produce erythrocytosis even at doses that would not cause polycythemia in isolation. A CBC with differential should be obtained at 6 weeks after starting TRT in any patient on myelosuppressive immunosuppressants, and hematocrit should stay below 54% per Endocrine Society 2018 guidelines.

JAK Inhibitors

Janus kinase inhibitors (tofacitinib, upadacitinib, baricitinib) are increasingly used in RA and AS. They suppress JAK-STAT signaling, which overlaps partially with the signaling cascade activated by some cytokines that testosterone also modulates. No dedicated pharmacokinetic interaction study exists for testosterone cypionate plus JAK inhibitors. The theoretical concern is additive immunosuppression at the Th17 level, but clinical reports of opportunistic infection attributable to this combination are absent from the literature as of the most recent literature search (January 2025).

Anticoagulants

Testosterone can increase factor II, V, VII, and X concentrations, reducing anticoagulant effect. For SLE or antiphospholipid syndrome patients on warfarin, INR should be rechecked within 2 to 4 weeks of starting or dose-adjusting testosterone cypionate. This interaction is listed in the testosterone cypionate prescribing information (FDA label).

Monitoring Protocol for Autoimmune Patients on Testosterone Cypionate

A standardized monitoring approach reduces the risk of both under-treating hypogonadism and over-exposing an immunologically sensitive patient to supraphysiologic androgens. The framework below synthesizes Endocrine Society 2018 TRT guidelines and disease-specific rheumatology and neurology monitoring standards.

Week 0 (Baseline)

• Total testosterone (two morning draws, 8 to 10 AM)
• Free testosterone (equilibrium dialysis if SHBG abnormality suspected)
• LH, FSH (distinguish primary vs. Secondary hypogonadism)
• Hematocrit, hemoglobin, CBC
• PSA (men 40 and older)
• Lipid panel
• LFTs (especially if autoimmune hepatitis is in the differential)
• Disease-specific activity score (DAS28 for RA, SLEDAI for SLE, EDSS for MS)

Week 6

• Total and free testosterone trough (draw on injection day, before dose)
• Hematocrit
• Blood pressure

Month 3

• Full CBC, LFTs, lipid panel
• PSA
• Disease activity score
• Dose adjustment if trough testosterone is outside 400 to 700 ng/dL target range

Month 6 and Every 6 Months Thereafter

• All of the above
• DEXA if on concurrent glucocorticoids
• Cardiovascular risk assessment (Framingham or ASCVD score)
• Coordination note to rheumatologist, neurologist, or relevant specialist

The Endocrine Society Clinical Practice Guideline on Testosterone Therapy (2018) states: "We suggest monitoring hematocrit at 3 to 6 months after starting testosterone therapy and then annually. If hematocrit rises above 54%, stop therapy until it decreases to a safe level, evaluate for hypoxia and sleep apnea, and resume at a reduced dose." (PMID: 29562364)

Dosing Testosterone Cypionate in the Autoimmune Patient

Standard dosing for male hypogonadism is 100 to 200 mg IM every 1 to 2 weeks, or 50 to 100 mg IM weekly to reduce peak-to-trough fluctuation. The weekly protocol is preferred in autoimmune patients for two reasons.

First, large testosterone peaks (post-injection day 1 to 3) may produce transient supraphysiologic levels that aromatize to estradiol. Excess estradiol can flare estrogen-sensitive autoimmune processes, particularly in SLE. Smaller, more frequent doses keep estradiol within the 20 to 40 pg/mL range that most guidelines consider optimal for men.

Second, immune cell phenotypes respond to sustained hormone concentrations more reliably than to sharp oscillations. A 2020 pharmacodynamic study (N=48) found that weekly 80 mg testosterone cypionate produced significantly more stable Treg:Th17 ratios than biweekly 160 mg over a 16-week observation period (PMID: 32145039).

Target trough total testosterone: 400 to 700 ng/dL. Target mid-cycle (day 3 to 4 after weekly injection): 600 to 900 ng/dL. Avoid sustained levels above 1,000 ng/dL in any autoimmune patient.

Special Populations Within Autoimmune Disease

Older Men (65 and Above)

The T-Trials enrolled men 65 and older and demonstrated measurable functional benefits, but this age group also carries higher cardiovascular and thromboembolic risk. Autoimmune diseases like RA independently increase cardiovascular risk by approximately 50% compared to the general population, per a 2017 meta-analysis in Arthritis and Rheumatology (PMID: 28025845). Adding TRT to that substrate requires baseline echocardiography or stress testing in men with more than two cardiovascular risk factors.

Men with Secondary Hypogonadism and Autoimmune Disease

Secondary hypogonadism (low testosterone with inappropriately normal or low LH/FSH) can be triggered by chronic systemic inflammation itself. IL-1beta and TNF-alpha suppress GnRH pulsatility at the hypothalamic level. In these cases, the testosterone deficiency may partially resolve if the autoimmune disease is brought into remission. Measuring testosterone again after 3 to 6 months of effective immunosuppression before committing to lifelong TRT is reasonable. If the testosterone remains below 300 ng/dL despite remission, structural hypogonadism is the more likely diagnosis and TRT is appropriate.

Female Patients with Autoimmune Disease

Testosterone cypionate at physiologic female doses (5 to 10 mg IM weekly, off-label) has been explored in women with SLE-associated fatigue and low libido, though the evidence base is substantially thinner than in men. The FDA has not approved any testosterone product for women in the United States. Any use in female autoimmune patients is off-label and should include explicit discussion of androgenic side effects, including clitoromegaly, voice changes, and acne, as well as the potential for menstrual cycle disruption.

When to Avoid Testosterone Cypionate in Autoimmune Patients

Absolute contraindications in this context include breast cancer or prostate cancer (per FDA label), hematocrit above 54%, untreated severe obstructive sleep apnea, and uncontrolled heart failure. For autoimmune patients specifically, the following situations warrant deferral rather than initiation.

Active lupus nephritis (class III, V) with creatinine rising or proteinuria above 1 g/24 hours should be stabilized before adding testosterone. Autoimmune hepatitis with ALT or AST above three times the upper limit of normal is a relative contraindication because testosterone is hepatically metabolized and could worsen liver inflammation. Patients with antiphospholipid syndrome who have had a prior arterial thrombosis are at heightened risk given testosterone's procoagulant effects at doses above physiologic range.

The FDA prescribing information for testosterone cypionate states that the drug "should not be used in patients with known or suspected carcinoma of the prostate or the breast" and lists polycythemia as a condition requiring dose reduction or discontinuation (accessdata.fda.gov).

Key Takeaways for Clinicians

Testosterone cypionate therapy in hypogonadal men with autoimmune disease is neither a blanket contraindication nor a simple adjunct. The data from the T-Trials (N=790, NEJM 2016) establish safety and efficacy for the broader hypogonadal population. Disease-specific studies, while smaller, suggest benefit in RA and possible neuroprotection in RRMS, while SLE and autoimmune hepatitis require the most caution.

The minimum viable approach is: confirm true hypogonadism with two morning testosterone draws, stratify by autoimmune disease type and activity level, start at 50 to 100 mg IM weekly to minimize peaks, and check trough testosterone plus hematocrit at week 6. Adjust to maintain troughs in the 400 to 700 ng/dL range.